The size of the Middle East and Africa Advanced Infusion Systems Market is estimated to grow at a slow rate during the forecast period.
The growth of the MEA advanced infusion systems market can be attributed to the increasing prevalence of chronic diseases, increased rate of population, and growing demand for minimally invasive procedures. Chronic diseases such as diabetes, hypertension, and cancer are increasing rapidly in developing, low- and middle-income regions around the MEA. The number of people with diabetes increased from 108 million in the early 1980s to 425 million in 2015. The global prevalence of diabetes among adults over 18 years of age rose to 8.58% in 2015, from 4.78% in 1980.
Other factors such as the increasing number of hospitals and clinics, more expenditure on healthcare are boosting the growth of the MEA advanced infusion systems market. Total health expenditure is growing faster than gross domestic product; in low-and-middle-income countries, the average is about 6.5%, while the average is at 4.4% in high-income countries. An advanced infusion system can offer efficient delivery of drugs, amino acids, minerals, and several essential micronutrients, creating opportunities in the MEA market. Companies aim to launch smart infusion systems with greater therapeutic efficacy and eliminate user risks, automation, drug libraries, operators, and safety features for precise and precise patient results to help manage controlled fluids in patient systems.
However, strict regulations regarding product approval and the high cost associated with advanced infusion systems may hamper the growth of this market. Moreover, concerns about the consequences of improper use and low-income countries that cannot afford to provide such systems to their medical units are the major causes that create obstacles for the growth of the MEA advanced infusion systems market. In addition, inappropriate disposal of infusion pumps leads to growing concerns for patient and environmental safety.
This research report on the MEA Advanced Infusion Systems Market is segmented & sub-segmented into the following categories:
By Application Type:
By Product Type:
The Kingdom of Saudi Arabia regional market holds the largest share of the MEA advanced infusion systems market due to the presence of prominent players, a large patient base, and the high adoption of infusion systems in chronic disease management in this region. The World Health Organization (WHO) has reported that Saudi Arabia ranks second in the Middle East region and seventh across the globe for having a high prevalence of diabetes. It is estimated that around 7.23 million people have diabetes, and nearly 3.21 million have prediabetes.
The regional market in Egypt is analyzed to hold the second-largest market share of the MEA advanced infusion systems market owing to the increase in healthcare spending, favorable reimbursement policies, and well-established healthcare infrastructure in this region. Diabetes is a rapidly growing health problem in Egypt with a significant impact on healthcare society affecting human resources. Based on recent data, in Egypt, the prevalence of type 2 diabetes is reported to be approximately 15.89% of all adults aged 20-79 years.
The regional market in South Africa is predicted to grow at a CAGR of 3% during the forecast period. This market growth can be attributed to the high adoption rate of these devices in hospitals, coupled with a growing awareness of their benefits, supportive local and international healthcare authorities to provide a better quality of medical facilities, and availability of funds to encourage research and development activities.
KEY MARKET PLAYERS:
Hospira, Inc. is a market leader in infusion technologies globally. The major players in these markets are AngioDynamics, Inc., Medtronic, Inc., Terumo Corporation, Johnson & Johnson, CareFusion Corporation, Animas Corporation, Baxter International, Inc., B. Braun Melsungen AG, I-Flow Corporation, and F. Hoffmann-La Roche Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com